Austar Lifesciences Vergangene Ertragsentwicklung

Vergangenheit Kriterienprüfungen 0/6

Austar Lifesciences steigerte seine Gewinne mit einer durchschnittlichen jährlichen Rate von 21.9%, während die Branche Life Sciences Gewinne von wachsend um 22.4% jährlich. Der Umsatz ist gewachsen mit einer durchschnittlichen Rate von 20.4% pro Jahr.

Wichtige Informationen

21.9%

Wachstumsrate der Gewinne

21.9%

EPS-Wachstumsrate

Life Sciences Wachstum der Industrie41.4%
Wachstumsrate der Einnahmen20.4%
Eigenkapitalrendite-4.5%
Netto-Marge-1.8%
Letzte Ertragsaktualisierung31 Dec 2023

Jüngste Aktualisierungen vergangener Leistungen

Recent updates

We Think Shareholders May Want To Consider A Review Of Austar Lifesciences Limited's (HKG:6118) CEO Compensation Package

May 24
We Think Shareholders May Want To Consider A Review Of Austar Lifesciences Limited's (HKG:6118) CEO Compensation Package

Revenues Working Against Austar Lifesciences Limited's (HKG:6118) Share Price Following 30% Dive

Apr 18
Revenues Working Against Austar Lifesciences Limited's (HKG:6118) Share Price Following 30% Dive

Would Austar Lifesciences (HKG:6118) Be Better Off With Less Debt?

Mar 28
Would Austar Lifesciences (HKG:6118) Be Better Off With Less Debt?

Investors Still Aren't Entirely Convinced By Austar Lifesciences Limited's (HKG:6118) Revenues Despite 25% Price Jump

Feb 12
Investors Still Aren't Entirely Convinced By Austar Lifesciences Limited's (HKG:6118) Revenues Despite 25% Price Jump

Market Cool On Austar Lifesciences Limited's (HKG:6118) Revenues

Dec 22
Market Cool On Austar Lifesciences Limited's (HKG:6118) Revenues

We Think Austar Lifesciences (HKG:6118) Has A Fair Chunk Of Debt

Sep 28
We Think Austar Lifesciences (HKG:6118) Has A Fair Chunk Of Debt

Here's Why Austar Lifesciences (HKG:6118) Has A Meaningful Debt Burden

Mar 31
Here's Why Austar Lifesciences (HKG:6118) Has A Meaningful Debt Burden

Austar Lifesciences Limited (HKG:6118) Stock's 29% Dive Might Signal An Opportunity But It Requires Some Scrutiny

Sep 19
Austar Lifesciences Limited (HKG:6118) Stock's 29% Dive Might Signal An Opportunity But It Requires Some Scrutiny

Is Austar Lifesciences (HKG:6118) A Risky Investment?

Apr 06
Is Austar Lifesciences (HKG:6118) A Risky Investment?

Austar Lifesciences (HKG:6118) Has A Pretty Healthy Balance Sheet

Oct 24
Austar Lifesciences (HKG:6118) Has A Pretty Healthy Balance Sheet

With EPS Growth And More, Austar Lifesciences (HKG:6118) Is Interesting

Sep 27
With EPS Growth And More, Austar Lifesciences (HKG:6118) Is Interesting

If You Like EPS Growth Then Check Out Austar Lifesciences (HKG:6118) Before It's Too Late

May 31
If You Like EPS Growth Then Check Out Austar Lifesciences (HKG:6118) Before It's Too Late

Austar Lifesciences (HKG:6118) Seems To Use Debt Quite Sensibly

Mar 31
Austar Lifesciences (HKG:6118) Seems To Use Debt Quite Sensibly

Is Now The Time To Put Austar Lifesciences (HKG:6118) On Your Watchlist?

Mar 01
Is Now The Time To Put Austar Lifesciences (HKG:6118) On Your Watchlist?

Austar Lifesciences Limited (HKG:6118) Stock Is Going Strong But Fundamentals Look Uncertain: What Lies Ahead ?

Feb 01
Austar Lifesciences Limited (HKG:6118) Stock Is Going Strong But Fundamentals Look Uncertain: What Lies Ahead ?

Are Austar Lifesciences's (HKG:6118) Statutory Earnings A Good Guide To Its Underlying Profitability?

Jan 11
Are Austar Lifesciences's (HKG:6118) Statutory Earnings A Good Guide To Its Underlying Profitability?

Austar Lifesciences (HKG:6118) Seems To Use Debt Quite Sensibly

Dec 21
Austar Lifesciences (HKG:6118) Seems To Use Debt Quite Sensibly

Can You Imagine How Jubilant Austar Lifesciences' (HKG:6118) Shareholders Feel About Its 191% Share Price Gain?

Dec 07
Can You Imagine How Jubilant Austar Lifesciences' (HKG:6118) Shareholders Feel About Its 191% Share Price Gain?

Here's What Austar Lifesciences Limited's (HKG:6118) Shareholder Ownership Structure Looks Like

Nov 23
Here's What Austar Lifesciences Limited's (HKG:6118) Shareholder Ownership Structure Looks Like

Aufschlüsselung der Einnahmen und Ausgaben

Wie Austar Lifesciences Geld verdient und ausgibt. Basierend auf den neuesten gemeldeten Einnahmen der letzten zwölf Monate.


Gewinn- und Umsatzhistorie

SEHK:6118 Einnahmen, Ausgaben und Erträge (CNY Millions)
DatumEinnahmenUmsatzAllgemeine und VerwaltungskostenF&E-Ausgaben
31 Dec 231,764-3333355
30 Jun 232,089234364
31 Mar 232,1594532767
31 Dec 222,15710430370
30 Sep 222,2469630771
30 Jun 222,26410530472
31 Mar 222,13919130469
31 Dec 212,01527730466
30 Sep 211,82425830459
30 Jun 211,63323830452
31 Mar 211,46513628150
31 Dec 201,2963325948
30 Sep 201,1932525347
30 Jun 201,0891724645
31 Mar 201,0691224844
31 Dec 191,049825143
30 Sep 191,007823439
30 Jun 19966821636
31 Mar 19891420033
31 Dec 18817018330
30 Sep 18724-1618229
30 Jun 18631-3318228
31 Mar 18589-4317727
31 Dec 17547-5417126
30 Sep 17587-4316027
30 Jun 17628-3214928
31 Mar 17650-2515030
31 Dec 16673-1915132
30 Sep 16648-1714632
30 Jun 16624-1614131
31 Mar 16626-513429
31 Dec 15628612727
30 Sep 156402412226
30 Jun 156524311826
31 Mar 156665412025
31 Dec 146806512224
30 Sep 146765812824
30 Jun 146725113324
31 Mar 146895212624
31 Dec 137055412024

Qualität der Erträge: 6118 ist derzeit unrentabel.

Wachsende Gewinnspanne: 6118 ist derzeit unrentabel.


Analyse von freiem Cashflow und Gewinn


Analyse des Gewinnwachstums in der Vergangenheit

Ergebnisentwicklung: 6118 ist unrentabel, hat aber in den letzten 5 Jahren die Verluste mit einer Rate von 21.9% pro Jahr reduziert.

Beschleunigtes Wachstum: Das Gewinnwachstum des letzten Jahres kann nicht mit dem 5-Jahres-Durchschnitt von 6118 verglichen werden, da das Unternehmen derzeit nicht profitabel ist.

Erträge im Vergleich zur Industrie: 6118 ist unrentabel, was einen Vergleich des Gewinnwachstums des letzten Jahres mit der Branche Life Sciences (0.4%) erschwert.


Eigenkapitalrendite

Hohe Eigenkapitalrendite: 6118 hat eine negative Eigenkapitalrendite (-4.49%), da es derzeit unrentabel ist.


Kapitalrendite


Rendite auf das eingesetzte Kapital


Entdecken Sie starke Unternehmen, die in der Vergangenheit erfolgreich waren